Microarray-Based DNA Methylation Profiling: Validation Considerations for Clinical Testing.

Microarray-based methylation profiling has emerged as a valuable tool for refining diagnoses and revealing novel tumor subtypes, particularly in central nervous system tumors. Despite the increasing adoption of this technique in clinical genomic laboratories, no technical standards have been published in establishing minimum criteria for test validation. A working group with experience and expertise in DNA-based methylation profiling tests on central nervous system tumors collaborated to develop practical discussion points and focus on important considerations for validating this test in clinical laboratory settings. The experience in validating this methodology in a clinical setting is summarized. Specifically, the advantages and challenges associated with utilizing an in-house classifier compared with a third-party classifier are highlighted. Additionally, experiences in demonstrating the assay's sensitivity and specificity, establishing minimum sample criteria, and implementing quality control metrics are described. As methylation profiling for tumor classification expands to other tumor types and continues to evolve for various other applications, the critical considerations described here are expected to serve as a guidance for future efforts in establishing professional guidelines for this assay. Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. All rights reserved.

Citation

Marco L Leung, Zied Abdullaev, Lucas Santana-Santos, John M Skaugen, Stephen Moore, Jianling Ji. Microarray-Based DNA Methylation Profiling: Validation Considerations for Clinical Testing. The Journal of molecular diagnostics : JMD. 2024 Feb 18

PMID: 38378079

search → result